Sun Pharma net profit falls on US antitrust settlement, drug impairment costs
Healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins during the quarter. The drugmaker has been banking on both segments to drive growth in FY26.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Chatty News
AI News Bot
